Inventiva (IVA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

IVA Stock Forecast

Inventiva stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

IVA Analyst Ratings

Buy

According to 3 Wall Street analysts, Inventiva's rating consensus is 'Buy'. The analyst rating breakdown for IVA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 26, 2024	H.C. Wainwright	Buy	Buy	Hold
May 20, 2024	Canaccord Genuity	Buy	Buy	Hold
Apr 08, 2024	Canaccord Genuity	Buy	Buy	Hold
May 19, 2023	Societe Generale		Buy	Upgrade

Inventiva's last stock rating was published by H.C. Wainwright on Sep 26, 2024. The company gave IVA a "Buy" rating, the same as its previous rate.

Inventiva Financial Forecast

Inventiva Revenue Forecast

	Mar 28	Dec 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$3.74M	$3.74M	$7.06M	$13.98M	$6.03M	$14.35M	$1.15M	$3.20M	$4.54M	$3.77M	$3.77M	$3.59M	$1.20M	$2.56M	$18.27M	$1.37M
High Forecast	$3.74M	$3.74M	$7.06M	$13.98M	$6.03M	$14.35M	$1.15M	$3.20M	$4.54M	$3.77M	$3.77M	$3.59M	$1.20M	$2.56M	$18.27M	$1.37M
Low Forecast	$3.74M	$3.74M	$7.06M	$13.98M	$6.03M	$14.35M	$1.15M	$3.20M	$4.54M	$3.77M	$3.77M	$3.59M	$1.20M	$2.56M	$18.27M	$1.37M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Inventiva's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IVA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Inventiva EBITDA Forecast

	Mar 28	Dec 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-3.74M	$-3.74M	$-7.06M	$-13.98M	$-6.03M	$-14.35M	$-1.15M	$-3.20M	$-4.54M	$-3.77M	$-3.77M	$-3.59M	$-1.20M	$-2.56M	$-18.27M	$-1.37M
High Forecast	$-3.74M	$-3.74M	$-7.06M	$-13.98M	$-6.03M	$-14.35M	$-1.15M	$-3.20M	$-4.54M	$-3.77M	$-3.77M	$-3.59M	$-1.20M	$-2.56M	$-18.27M	$-1.37M
Low Forecast	$-3.74M	$-3.74M	$-7.06M	$-13.98M	$-6.03M	$-14.35M	$-1.15M	$-3.20M	$-4.54M	$-3.77M	$-3.77M	$-3.59M	$-1.20M	$-2.56M	$-18.27M	$-1.37M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict IVA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Inventiva's previous annual EBITDA (undefined) of $NaN.

Inventiva Net Income Forecast

	Mar 28	Dec 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-50.81M	-	$-62.85M	$-40.02M	$-60.23M	$-26.99M	$-42.95M	$-42.55M	$-38.98M	$-32.73M	$-30.64M	$-53.33M	$-37.51M	$-37.93M	$70.63M	$-19.05M
High Forecast	$-50.81M	-	$-62.85M	$-40.02M	$-60.23M	$-26.99M	$-42.95M	$-42.55M	$-38.98M	$-32.73M	$-30.64M	$-53.33M	$-37.51M	$-37.93M	$70.63M	$-19.05M
Low Forecast	$-50.81M	-	$-62.85M	$-40.02M	$-60.23M	$-26.99M	$-42.95M	$-42.55M	$-38.98M	$-32.73M	$-30.64M	$-53.33M	$-37.51M	$-37.93M	$70.63M	$-19.05M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Inventiva's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IVA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Inventiva SG&A Forecast

	Mar 28	Dec 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$22.38M	$22.38M	$42.25M	$83.63M	$36.07M	$85.85M	$6.89M	$19.16M	$27.18M	$22.57M	$22.57M	$21.49M	$7.16M	$15.33M	$108.52M	$8.22M
High Forecast	$22.38M	$22.38M	$42.25M	$83.63M	$36.07M	$85.85M	$6.89M	$19.16M	$27.18M	$22.57M	$22.57M	$21.49M	$7.16M	$15.33M	$108.52M	$8.22M
Low Forecast	$22.38M	$22.38M	$42.25M	$83.63M	$36.07M	$85.85M	$6.89M	$19.16M	$27.18M	$22.57M	$22.57M	$21.49M	$7.16M	$15.33M	$108.52M	$8.22M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Inventiva's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IVA last annual SG&A of $NaN (undefined).

Inventiva EPS Forecast

	Mar 28	Dec 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.98	-	$-1.21	$-0.77	$-1.16	$-0.52	$-0.83	$-0.82	$-0.75	$-0.63	$-0.63	$-1.03	$-0.72	$-0.73	$1.45	$-0.37
High Forecast	$-0.98	-	$-1.21	$-0.77	$-1.16	$-0.52	$-0.83	$-0.82	$-0.75	$-0.63	$-0.63	$-1.03	$-0.72	$-0.73	$1.45	$-0.37
Low Forecast	$-0.98	-	$-1.21	$-0.77	$-1.16	$-0.52	$-0.83	$-0.82	$-0.75	$-0.63	$-0.63	$-1.03	$-0.72	$-0.73	$1.45	$-0.37
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Inventiva's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IVA previous annual EPS of $NaN (undefined).

Inventiva Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VRCA	Verrica Pharmaceuticals	$0.70	$12.00	1614.29%	Buy
IVA	Inventiva	$2.28	$36.00	1478.95%	Buy
VTYX	Ventyx Biosciences	$2.37	$33.86	1328.69%	Buy
VIGL	Vigil Neuroscience	$1.73	$11.00	535.84%	Buy
IPHA	Innate Pharma	$2.15	$10.00	365.12%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
CMPX	Compass Therapeutics	$1.53	$5.00	226.80%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
IMCR	Immunocore	$29.40	$70.20	138.78%	Buy
PCVX	Vaxcyte	$89.86	$148.80	65.59%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
RZLT	Rezolute	$4.44	$6.67	50.23%	Buy
NAMS	NewAmsterdam Pharma Company	$26.61	$39.33	47.80%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy
JANX	Janux Therapeutics	$59.61	$70.25	17.85%	Buy

IVA Forecast FAQ

Is Inventiva a good buy?

Yes, according to 3 Wall Street analysts, Inventiva (IVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of IVA's total ratings.

What are Inventiva's analysts' financial forecasts?

Inventiva's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $24.73M (high $24.73M, low $24.73M), average EBITDA is $-24.729M (high $-24.729M, low $-24.729M), average net income is $-173M (high $-173M, low $-173M), average SG&A $147.97M (high $147.97M, low $147.97M), and average EPS is $-3.323 (high $-3.323, low $-3.323). IVA's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $24.78M (high $24.78M, low $24.78M), average EBITDA is $-24.779M (high $-24.779M, low $-24.779M), average net income is $-103M (high $-103M, low $-103M), average SG&A $148.26M (high $148.26M, low $148.26M), and average EPS is $-1.979 (high $-1.979, low $-1.979).